To improve uptake and cross-presentation of exogenous antigens (Ag) by dendritic cells (DCs), octaarginine-modified liposomes (R8-Lip) were used as a novel strategy for protein-Ag transduction. Immature DCs endocytose macromolecules efficiently. While mature DCs lose their ability to capture Ag, but have an increased capacity for T-cell activation. Thus Ag-transduction has been performed mostly in immature DCs. In the present study, R8-Lip were efficiently taken up by both immature and mature DCs.
INTRODUCTION
The unique ability of dendritic cells (DCs) to take up, process and present antigens (Ag), and to activate naïve CD4+ and CD8+ T cells raises the possibility of using DCs as "nature vaccines" [1, 2] . So far, the efficiency of Ag-loaded DCs to induce immunity against tumors and viral infectious diseases has been tested in a number of pre-clinical trials [1] [2] [3] . Although DCs-based immunotherapy presents a promising approach, optimization of DCs-vaccination protocols is still needed to enhance the success of future clinical trials [3] . In most trials, Ag was loaded into DCs in vitro and the cells were then administered to patients.
One of limiting steps in dendritic cells (DCs)-based vaccination is the maturation stage of the cells. Immature DCs specialize in Ag capture, whereas mDCs have a low capacity for Ag uptake capacity, but an increased ability to stimulate T-cells [4, 5] . Because the Ag uptake by DCs decreases as the cells mature from iDCs to mDCs, most groups have used iDCs to promote Ag capture and uptake [6] . To facilitate the Ag uptake by DCs, arginine-rich cell-penetrating peptides (CPPs) including HIV-TAT, poly-arginine and penetratin (Int) derived from Antennapedia has been applied recently [7] [8] [9] [10] . Kim et al. were the first to demonstrate that Ag-specific cytotoxic T lymphocytes (CTLs) are generated in vivo by immunizing mice with DCs that had been exposed to protein-TAT conjugates [7] . Since then various research groups, including our own, have applied CPP transduction to DCs as a method of stimulating Ag-specific T cells. Many studies reported that mice immunized with DCs transduced with recombinant CPP-Ag protein suppressed the tumor growth significantly [8] [9] [10] [11] [12] [13] [14] [15] . Apart from the recombinant fusion protein, synthetic polypeptide containing CPP tandemly linked to peptide epitopes is another striking approach [14] . Although recombinant proteins or peptides containing CPPs are attractive prospects, a specific construct needs to be made. In addition, peptide synthesis and construction/ purification of such fusion proteins are tedious and complex work.
Recently our group has constructed a simple and efficient vaccine delivery system so called "ocataarginine-modified liposomes" (R8-Lip), in which the encapsulated Ag can be delivered, processed and presented to specific T-cells efficiently [16] . We have found that R8-Lip with Ag encapsulated induced a strong anti-tumor effect in a mouse model. In the present study, we demonstrate that R8-Lip can be taken up by DCs efficiently, regardless of DCs maturation stage. The escape of R8-Lip from endosomes to the cytosol was highly efficient in mDCs and the released Ag were processed via the proteasome-dependent pathway. Interestingly, we found that when the order of Ag-loading and DCs maturation is reversed; that is DCs maturation is induced first, followed by the Ag-transduction by R8-Lip, the pMHC class I presentation and CTL activities have markely improved. These findings would be an advantage for further development of DCs-based vaccination.
Materials and Methods

Materials
Dioleoyl phosphatidylethanolamine (DOPE) and egg phosphatidylcholine (EPC) were purchased from Avanti Polar Lipids (Alabaster, AL). Cholesteryl hemisuccinate (CHEMS) was obtained from SIGMA-Aldrich Co. (St. Louis, MO). Sulforhodamine B, and Lysotracker Red were purchased from Molecular Probes (Eugene, OR).
Stearylated-octaarginine (STR-R8) was synthesized as described previously [17] .
Synthetic oligodeoxynucleotides (ODN) containing CpG motifs (CpG 1668; 5'-TCCATGACGTTCCTGATGCT-3') were purchased from Hokkaido System Science (Sapporo, Japan). Other chemicals were purchased from Wako Chemicals (Osaka, Japan)
Preparation of R8-modified liposomes encapsulating OVA antigens
Liposomes were comprised of DOPE, CHEMS, and EPC in a molar ratio of 7.5:1:1.5.
The desired amount of each lipid in chloroform was dried under a nitrogen stream. The lipid was then hydrated by adding 1 ml 10 mM Hepes buffer, containing OVA (5 mg OVA), and incubating the mixture for 10 min at room temperature with gentle shaking. Sulforhodamine B was used as an aqueous phase marker, when required. Preparations were then sonicated and subjected to six freeze-thaw cycles. The vesicle diameter was controlled by sequentially extruding the preparation through polycarbonate membrane filters with a pore size of 400 nm. Then, any OVA that was not associated with the liposomes was removed by ultracentrifugation at 80,000 x g (Himac CS150 GX, Hitachi) for 30 min at 4 o C. The final liposome pellets were resuspended in 1 ml Hepes buffer. Surface modification of the resulting liposomes with polyarginine peptides was 6 accomplished by incubating the liposomes with an aqueous solution of STR-R8 (7.5 mol% total lipids) for 30 min at room temperature.
The diameter and zeta-potential of liposomes were measured using an electrophoretic light-scattering spectrophotometer (Zetasizer Nanoseries, Malvern Instruments, Malvern UK). The concentration of phospholipids in the liposome suspension was measured by the cholineoxidase method using Phospholipid C-Test (Wako Pure Chemical Industries, Osaka, Japan). The amount of entrapped OVA was quantified after lipid removal, according to the method of Peterson [18] .
Dendritic cells generation
Bone marrow-derived DCs were obtained as described previously [19] . Briefly, bone marrow was flushed from femurs and tibias of C57BL/6 mice. After lysing the erythrocytes, cells were cultured in 24-well plates (10 6 cells/well) in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 50 mM 2-mercaptoethanol, 25 mM Hepes, 50 IU of penicillin and 50 g of streptomycin (PS) per ml in the presence of 500 U/ml of recombinant murine granulocyte macrophage colony stimulating factor (GM-CSF). The floating cells were replated on day 2. On days 3 and 4, nonadherent cells (newly formed granulocytes) were gently removed from the cultures, and fresh medium plus GM-CSF was added. On day 7, DCs were harvested and the cell yield was analyzed using Trypan blue staining.
Kinetics of liposome-uptake by dendritic cells
The kinetics of endocytosis of non-modified liposomes and octaargininemodified liposomes (R8-Lip) by DCs were quantitatively determined by flow cytometry. 
Transduction of iDCs and mDCs with liposomes
The procedure for transducing R8-Lip-OVA into either iDCs or mDCs is shown in schematic form in Fig. 1 . 
Antigen presentation assays
The level of OVA-derived peptide/MHC class I complexes (pMHC) expressed on DCs was determined by measuring of lacZ activity induced in B3Z CD8 + T-cell hybridomas, as described elsewhere with some modifications [20] . 
Immunizations and CTL assays
Purified DC, both immature and mature cells, were pulsed with R8-Lip-OVA as described above. The resulting DCs (7.5 x 10 5 ) were intradermally injected into four C57BL/6 mice at day 0. At day 7, the mice were given a second injection, using the same protocol. Then, on day 14, spleens were harvested and re-stimulated with an OVA-expressing K b -restricted tumor cell line, EG.7. Before use, the EG.7 cells were pretreated with mitomycin C (50 g/ml for 30 min) and were then added to the isolated splenocytes at a ratio of 10:1 (splenocytes:EG.7). Five days later, splenocytes were harvested and used as effector cells in the CTL assays.
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CTL assays were performed using a standard chromium-release assay. 
Results
Octaarginine liposomal formulation loaded with OVA
Octaarginine-modified liposomes encapsulating OVA (R8-Lip-OVA) were prepared according to the post insertion technique. The non-modified liposomes were first prepared and then these liposomes were incubated with stearylated octaarginine (STR-R8). During the incubation, the membrane-permeable peptides, R8, attach to the liposome surface. Values are mean ± S.D. (n = 6). Table 1 summarises the physical properties of the non-modified liposomes and R8-Lip-OVA, both encapsulating OVA. The presence of arginine octamers on the liposome surface resulted in a slight increase in particle size (~ca. 200 nm). As expected, nonmodified liposomes were negatively charged, as indicated by their zeta potential, whereas R8-Lip were positively charged.
Kinetic of liposomes uptake and DCs maturation
The relationship between liposomal uptake and maturation stage of DCs was This result indicates that liposomal uptake was enhanced by R8-surface modification.
Except for DCs harvested at 1 h, R8-Lip uptake decreased over time, but was still much greater than that of the non-modified liposomes. Maturation of DCs was verified by upregulation of CD86 expression. CD86 was sharply increased after 12 h of incubation with CpG-ODN.
Transduced mature DCs are more efficient at pMHC presentation to T cells than immature DCs
To compare the antigen presentation capacity of transduced iDCs and mDCs, DCs were cultured and pulsed with free OVA, non-modified liposomes loaded with OVA or R8-Lip-OVA. As shown in Fig. 3a (Fig. 3b) . Increasing the R8-Lip-OVA concentration from 0.025 to 0.1 mM, resulted in a 3.7-fold increase in pMHC presentation efficiency. However, for iDCs transduction (transduced 2 h  mat 22 h), there was no much difference in pMHC presentation efficiency observed for 0.025 to 0.075 mM of R8-Lip-OVA. We also found that the much larger amount of free OVA (over 1 mg/ml range) has to be used for the similar efficiency of pMHC presentation (data not shown).
Priming of cytotoxic lymphocytes after administration of R8-Lip transduced DCs
To test whether iDCs and mDCs treated with R8-Lip-OVA were able to stimulate OVA-specific CTL responses, DCs were incubated with R8-Lip-OVA (5 g OVA) and cells were then administered intradermally to naïve mice. The mice were given a booster injection of pulsed DCs one week after the first immunization. As shown in Fig. 4 , an OVA-specific CTL activity of splenocytes from mice immunized 16 with transduced mDCs was nearly twice that observed for splenocytes from mice immunized with transduced iDCs.
Figure 4
These implied that transduction with R8-Lip in mature stage was more efficiency than that in immature cells.
The role of macropinocytois and endosomes/lysosomes in the uptake and presentation of R8-Lip-OVA
To ascertain if the uptake of R8-Lip-OVA by DCs occurs via macropinocytosis, an inhibitor of Na + /H + exchange-amiloride-was used in the Ag-presentation assays.
No death or toxicity was observed after simultaneous treatment with the inhibitors and 17 R8-Lip (data not shown). Amiloride (1.0 mM) inhibited the presentation of pMHC by 65% and 85% for transduced iDCs and mDCs, respectively (Fig. 5 ).
Figure 5
The inhibition of pMHC presentation by amiloride suggests that uptake of R8-Lip-OVA involves macropinocytosis. The role of the endosome in Ag presentation was investigated using NH 4 Cl and chloroquin, which increase endosomal pH, preventing acidification of endosomes. Addition of NH 4 Cl (100 mM) to pulsed iDCs and mDCs, inhibited pMHC presentation to B3Z T cells by 45% and 35%, respectively (Fig. 5) . A similar result was obtained for the chloroquin inhibition studies. These results suggested that at less acidic endosomal pH of DCs the Ag encapsulating in R8-Lip has lower ability to access the MHC class I machineris.
MHC class I presentation after R8-Lip-OVA internalization is lactacystin sensitive
As shown in Fig. 6 , Ag-presentation by mDCs transduced with R8-Lip-OVA was somewhat inhibited by low concentration of lactacystin (1 and 10 M). The pMHC presentation was markedly inhibited at the higher concentration of lactacystin (by 40% and 50% at 25 and 50 M, respectively). However, pre-treatment of mDCs with leupeptin, an inhibitor of the endosomal protease cathepsin B, and of serine and cysteine proteases, had no effect on the presentation of pMHC to B3Z T cells.
These results suggest that pMHC class I presentation of Ag delivered by R8-Lip would occur mainly via the conventional MHC class I presentation pathway.
Compartmentalization of R8-Lip loaded with fluorescently labeled OVA in DCs
To visualize the intracellular localization of OVA in DCs, R8-Lip encapsulating fluorescein-labeled OVA were prepared. The potentials of iDCs and mDCs to take up R8-Lip containing FITC-OVA were then determined by confocal microscopy. The fate of labeled-OVA in iDCs and mDCs were visualized by staining DCs with LysoTracker
Red, which accumulates in endosomes and lysosomes. As shown in Fig. 7A , most of the labeled-OVA (green fluorescent) in iDCs was colocalized with LysoTracker (as indicated by yellow arrows). Only some of the labeled-OVA was observed at the cellular membrane and intracellularly, but not co-localized with LysoTracker staining (as indicated by white arrows). In contrast, Lysotracker and labeled-OVA were clearly distinguished at unique intracellular locations (white arrows) in mDCs (Fig. 7B) . Thus, these results suggest that the OVA encapsulated in R8-Lip escapes from the endosomes and lysosomes of DCs, particularly in the case of mDCs.
Discussion
A critical process in the activation of CTLs is the efficiency of DCs in picking up and processing Ag into the MHC class I presentation pathway. This pathway is currently called "cross-presentation" pathway [4, 21] . In an attempt to enhance the cellular uptake and promote the cross-presentation pathway in DCs, many investigators perused the recombinant fusion protein or synthetic peptides which contain CPPs tandemly linked to the Ag [7] [8] [9] [10] [11] [12] [13] [14] . However the construction of such a recombinant proteins/ peptides are specific for a single Ag, limiting the usefulness of this technology.
Recently, we have reported the novel vaccine delivery system, R8-Lip, which can for CTL induction [24, 26] . In the present study, we also found that transduction of mDCs with R8-Lip was preferrential over transduction of iDCs.
The transduced iDCs and mDCs exhibited similar immunophenotypes and maturation potentials, regardless of when they were transduced with R8-Lip-OVA (data not shown). DCs transduced with R8-Lip-OVA after maturation were by far superior in presenting pMHC as compared to those transduced in the immature stage (Fig. 3) . In addition, a correlation between in vitro pMHC presentation capacity of DCs and cytolytic activity against specific target cells, EG.7, was observed in this study. Mice injected intradermally with R8-Lip-OVA transduced mDCS (mat 22 h  transduced 2 h) revealed relatively high CTL activity (Fig. 4) , consistent with the high in vitro pMHC presentation. Our results were in agreement with many studies, which reported that transduction of mDCs with recombinant fusion proteins containing HIV-Tat was preferential over transduction of iDCs [8, 12, 13] . The longevity of pMHC on the surface of mDCs might be an advantage of pulsing Ag to DCs after their maturation [27, 28] . The pMHC on the surface of mDCs is more stable and there is less membrane turnover compared with iDCs [27] [28] [29] . It is possible that transduction of mDCs with recombinant CPPs or R8-Lip allows DCs to process and present internalized Ag to Tcells using newly synthesized MHC class I molecules. As a consequence, transduction of mDCs with R8-Lip-OVA showed higher pMHC class I presentation and CTL activity.
To a large extent, the efficiency of pMHC presentation is dependent on the concentration of pMHC complexes on the DCs surface [4, 21] . A presentation of pMHC derived from exogenous protein is inefficient, since it requires relatively high concentration of proteins Ag -in the mg/ml range [21] . However, R8-Lip-OVA were 22 capable of inducing MHC class I presentation of OVA epitope at a relatively low dose (2 g). The efficiency of pMHC presentation was also greater with the higher concentration of R8-Lip-OVA (Fig. 3b) , but still required a small quantity of Ag (in a g/ml range). This novel transduction method would be an advantage if multiple Ag, such as various CTL epitopes, coule be simultaneously codelivered and cross-presented efficiently even at low concentration.
The intracellular trafficking path of Ag determines the resulting presentation modality. In agreement with our previous studies, treatment of either iDCs or mDCs with amiloride (a macropinocytotic inhibitor) reduced pMHC presentation significantly Earlier studies reported that CPPs, such as Tat, polyarginine and Int, escaped the endosomes and that release from the endosome was dependent on acidification of the endosomes [32, 33] . The endosomal compartment usually is acidic due to the action of proton-pumping ATPase located in the endosomal membrane [34] . We found that an increase in endosomal pH, upon incubation with lysosomotropic agents (NH 4 Cl and chloroquin), impaired the efficiency of cross-presentation (Fig. 5) . These results suggested that the acidic environment of endosomes plays an important role in pMHC class I presentation of Ag encapsulating in R8-Lip. To elucidate the mechanism of Ag presentation in mDCs delivered by R8-Lip, the mature cells were incubated with lactacystin (a specific proteasome inhibitor) or leupeptin (an endosomal proteases inhibitor). Only lactacystin showed the markedly inhibition of pMHC presentation ( reported that the induction of maturation lowers endosomal/ lysosomal pH by ~1 pH unit, from pH 5.5 to pH 4.5 [34, 35] . The acidified endosomes of mDCs may be preferable for R8-Lip-OVA escape from endosomal compartments. Consequently, Agprocessing and presentation are more efficient in transduced mDCs than in transduced iDCs.
In summary, the present study demonstrated that R8-Lip are an excellent delivery system for transducing DCs with protein or peptide Ag. The simplicity and versatility of R8-Lip preparation would be a potentially Ag transduction method into DCs, which the whole tumor associated Ag or even tumor lysates could be delivered instead of single minimal peptide epitopes. Notably, the transduction of DCs by R8-Lip at the end of maturation process represents a logistical approach in the production of Ag-transduced DCs for clinical studies. Both type of liposomes were made of DOPE/CHEMS/EPC (7.5/1/1.5 molar ratio) and ovalubumin (OVA) was encapsulated into the liposomes. For R8-modified liposomes, the lipid membrane was modified with the cell penetrating peptide, R8 (7.5 mol%), to improve cellular uptake and intracellular trafficking. The endosome/ lysosome compartments of DCs were stained with LysoTracker Red.
Legends of Table and Figures
The labeled-OVA co-localized with LysoTracker Red in immature DCs, as indicated by
